• Skip to primary navigation
  • Skip to main content
  • Skip to footer
MotherToBaby

MotherToBaby

Medications and More during pregnancy and breastfeeding

Hide Search
Show Search
866.626.6847
  • About
    • Our Work
    • Our Team
    • Our Partners
  • Exposures
    • Pregnancy & Breastfeeding Exposures
    • Fact Sheets
    • Baby Blogs
    • Podcasts
  • Studies
    • Ongoing Studies
    • Pregnant Women
    • Join Now
    • Health Providers
    • Pharma Industry
    • Publications
  • Health Professionals
    • Patient Education and Provider Resources
    • Refer a Patient
    • Request Materials
    • Meetings
    • FAQs
    • OTIS Membership
  • Media
    • Press Releases
    • Media Requests
  • In Your Area
  • OTIS
    • About OTIS
    • OTIS Membership
    • Annual Meeting
    • Member Log-In
    • Donate
  • Contact

Oxcarbazepine

July 1, 2020

Selected References

  • Artama M, et al. 2006. Antiepileptic drug use and birth rate in patients with epilepsy-a population-based cohort study in Finland. Hum Reprod; 21:2290-5.
  • Blotiere PO, et al. 2019. Risks of 23 specific malformations associated with prenatal exposure to 10 antiepileptic drugs. Neurology; 93(2):e167-e80.
  • Bruno MK, Harden CL. 2002. Epilepsy in Pregnant Women. Curr Treat Options Neurol; 4(1):31-40.
  • Bülau P, et al. 1988. Pharmacokinetics of oxcarbazepine and 10-hydroxy-carbazepine in the newborn child of an oxcarbazepine-treated mother. Eur J Clin Pharmacol; 34:311–3.
  • Chen CY, et al. 2017. In utero oxcarbazepine exposure and neonatal abstinence syndrome: Case report and brief review of the literature. Pharmacotherapy; 37:e71–e5.
  • Christensen J, et al. 2015. Apgar-score in children prenatally exposed to antiepileptic drugs: a population-based cohort study. BMJ Open; 5(9):e007425.
  • Cohen JM, et al. 2019. Anticonvulsant Mood Stabilizer and Lithium Use and Risk of Adverse Pregnancy Outcomes. J Clin Psychiatry. 2019;80(4).
  • Eisenschenk S. 2006. Treatment with oxcarbazepine during pregnancy. Neurologist; 12(5):249-254.
  • Friis ML, et al. 1993. Therapeutic experiences with 947 epileptic out-patients in oxcarbazepine treatment. Acta Neurol Scand; 87(3):224-227.
  • Gentile S. 2003. Oxcarbazepine in pregnancy and lactation. Clin Drug Investig; 23:687.
  • Hvas CL, et al. 2000. Epilepsy and pregnancy: effect of antiepileptic drugs and lifestyle on birthweight. Br J Obstet Gynaecol; 107:896-902.
  • Isojarvi JI, et al. 2004. Effect of epilepsy and antiepileptic drugs on male reproductive health. Neurology; 62:247-53.
  • Jacobsen PE, et al. 2014. Prenatal exposure to antiepileptic drugs and dental agenesis. PLoS One; 9(1):e84420.
  • Kaaja E, et al. 2003. Major malformations in offspring of women with epilepsy. Neurology; 60:575-9.
  • Lloyd P, et al. 1994. Clinical Pharmacology and Pharmacokinetics of Oxcarbazepine. Epilepsia; 35(s3).
  • Lutz UC, et al. 2007. Oxcarbazepine treatment during breast-feeding: a case report. J Clin Psychopharmacol; 27:730–2.
  • Meischenguiser R, et al. 2003. Major malformations in offspring of women with epilepsy. [Letter] Neurology; 61:1631.
  • Meischenguiser R, et. al. 2004. Oxcarbazepine in pregnancy: clinical experience in Argentina. Epilepsy Behav; 5:163-167.
  • Miller M, et al. 2003. Major malformations in offspring of women with epilepsy. [Letter] Neurology; 61:1631.
  • Mølgaard-Nielsen D, Hviid A. 2011. Newer-generation antiepileptic drugs and the risk of major birth defects. JAMA; 305(19):1996-2002.
  • Montouris G. 2005. Safety of the newer antiepileptic drug oxcarbazepine during pregnancy. Curr Med Res Opin; 21:693-701.
  • Novartis Trileptal® Product Label. Available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021014s026,021285s021lbl.pdf [Accessed 7/2020].
  • Rolnitsky A, et al. 2013. In utero oxcarbazepine and a withdrawal syndrome, anomalies, and hyponatremia. Pediatr Neurol. 2013;48(6):466-8.
  • Tomson T, et al. 2015. Antiepileptic drugs and intrauterine death: A prospective observational study from EURAP. Neurology 85: 580-588.
  • Tomson T, et al. 2018. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurol; 17(6):530-538.
  • Veiby G, et al. 2014. Fetal growth restriction and birth defects with newer and older antiepileptic drugs during pregnancy. J Neurol 261: 579-588.
  • Videman M, et al. 2016. Evidence for spared attention to faces in 7-month-old infants after prenatal exposure to antiepileptic drugs. Epilepsy Behav; 64(Pt A):62-68.
  • Weston J, et al. 2016. Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child. Cochrane Database Syst Rev; 11(11):CD010224.
  • Wu D, et al. 2018. The effects of oxcarbazepine, levetiracetam, and lamotrigine on semen quality, sexual function, and sex hormones in male adults with epilepsy. Epilepsia. 59(7):1344-1350.

Footer

           

Hot Links

  • Home
  • Exposures
  • Fact Sheets
  • Baby Blogs
  • Podcasts
  • Pregnancy Studies
  • Join a Study Now
  • Healthcare Professionals
  • Refer a Patient
  • Request Materials
  • News
  • Donate
  • Ask An Expert

Current Studies

  • Ankylosing Spondylitis
  • Asthma
  • Coronavirus (COVID-19)
  • Crohn’s Disease
  • Eczema (Moderate-to-Severe)/Atopic Dermatitis
  • Juvenile Idiopathic Arthritis
  • Multiple Sclerosis
  • Pertussis/Tdap vaccine (“Whopping Cough” vaccine)
  • Psoriasis
  • Psoriatic Arthritis
  • Rheumatoid Arthritis
  • Ulcerative Colitis

Contact

Exposure Information Service
866.626.6847

Pregnancy Studies
877.311.8972

Media Inquiries
619.368.3259
nchavez@mothertobaby.org

MotherToBaby, a service of the Organization of Teratology Information Specialists
OTIS Logo

OTIS National Office
5034A Thoroughbred Lane
Brentwood, TN 37027

Copyright © 2021 The Organization of Teratology Information Specialists

  • Accessibility
  • Privacy
  • Terms
  • Site Map
^